title: Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin.
authors.forename: Amrita
authors.initials: A
authors.lastname: Desai
authors.forename: Gladys H
authors.initials: GH
authors.lastname: Telang
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Olszewski
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000079963:Brentuximab Vedotin; D004334:Drug Administration Schedule; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000009:adverse effects; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction / Q000379:methods; D012878:Skin Neoplasms / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin